Clinical Trial Update: Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating an abbreviated Rituximab-CHOP regimen in completely excised stage I/II diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Cyclophosphamide (Cytoxan) (cyclophosphamide)
• Doxorubicin (Adriamycin) (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (Rituxan) (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Asan Medical Center | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN